Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$66.08 USD

66.08
2,592

-0.22 (-0.33%)

Updated Apr 16, 2024 09:47 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ANIP

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

ANI Pharmaceuticals, Inc. [ANIP]

Reports for Purchase

Showing records 1 - 20 ( 88 total )

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/04/2024

Company Report

Pages: 7

Cortrophin Gel Strength Drive 2024 Guidance Upside; Under- Levered, Looking to Build Out Rare Disease Biz; Raise to $83

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for ANIP 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

11/09/2023

Company Report

Pages: 8

Gx and Established Brand Normalization Not Shocking; Cortrophin Is the Value Driver Here; Reiterate $73 Target and Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

08/22/2023

Company Report

Pages: 7

Raising Target to $73 With Outperformance Across the Business

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/09/2023

Company Report

Pages: 7

Very Large 1Q Beat; Raised Guidance Now Looks Conservative; Raise PT to $60

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

03/13/2023

Company Report

Pages: 7

2023 Guidance Ahead of Us, and Likely Conservative Based on Recent Track Record; Raise PT to $53; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

02/21/2023

Company Report

Pages: 5

Moderating 2023 Estimates Ahead of Likely Conservative Guidance; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 5.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/14/2022

Company Report

Pages: 7

3Q22: Solid Execution Across Entire Business; Cortrophin Gel Rx Growth Portends 4Q Acceleration; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

09/07/2022

Company Report

Pages: 24

Story Gelling Around Cortrophin Gel Growth Inflection; Initiate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 35.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ANIP

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

02/26/2018

Company Report

Pages: 4

We are dropping coverage due to reallocate our research resources.

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

11/03/2017

Daily Note

Pages: 6

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/02/2017

Company Report

Pages: 6

3Q17 Recap - Strong Trends and Pipeline Strength

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

08/04/2017

Daily Note

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

08/04/2017

Company Report

Pages: 7

2Q17 Recap - Strong Results in a Difficult Environment

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

05/05/2017

Company Report

Pages: 6

1Q17 Recap - Maintained Guidance, Progress on Corticotropin

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

05/05/2017

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

03/03/2017

Company Report

Pages: 6

Resetting the Base - Acquisitions Appear the Driver in 2017

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

03/03/2017

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ANI Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

02/27/2017

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party